AstraZeneca to acquire Gracell Biotechnologies for $1.2bn to expand cell therapy capabilities

AstraZeneca has announced a definitive agreement to acquire Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL) for an upfront cash payment of $1.0 billion, representing a 62% ... Read More